Daily Cosmetic Research Analysis
A mechanistic study identifies eucalyptol as a direct β2 integrin antagonist that curbs neutrophil trafficking and mitigates endotoxin-induced acute lung injury. In clinical surgery, a prospective neonatal case series supports single-incision laparoscopic endorectal pull-through with excellent functional and cosmetic outcomes, while a meta-analysis finds miniature laparoscopy yields less early postoperative pain than single-port laparoscopy in hysterectomy with comparable safety.
Summary
A mechanistic study identifies eucalyptol as a direct β2 integrin antagonist that curbs neutrophil trafficking and mitigates endotoxin-induced acute lung injury. In clinical surgery, a prospective neonatal case series supports single-incision laparoscopic endorectal pull-through with excellent functional and cosmetic outcomes, while a meta-analysis finds miniature laparoscopy yields less early postoperative pain than single-port laparoscopy in hysterectomy with comparable safety.
Research Themes
- Targeting neutrophil adhesion and chemotaxis via β2 integrin antagonism
- Minimally invasive techniques optimizing functional and cosmetic outcomes
- Evidence synthesis to guide surgical approach selection
Selected Articles
1. Chimonanthus salicifolius essential oil protects against endotoxin-induced acute lung injury via suppression of β2 integrin-mediated neutrophil adhesion and chemotaxis.
In a murine ALI model, Chimonanthus salicifolius essential oil reduced edema, cytokines, and neutrophil activation while inhibiting NF-κB signaling. Mechanistically, its component eucalyptol directly bound β2 integrin (MST Kd ~19.5 μM), disrupted β2 integrin/ICAM-1 interactions, and curtailed neutrophil adhesion and chemotaxis, translating into in vivo lung protection.
Impact: This work reveals a druggable neutrophil trafficking mechanism by identifying eucalyptol as a direct β2 integrin antagonist, linking ethnopharmacology to targeted anti-inflammatory therapy.
Clinical Implications: Targeting β2 integrin/ICAM-1 to dampen neutrophil trafficking could inform new therapies for ALI and potentially acute respiratory distress syndrome (ARDS) and other neutrophil-driven conditions, pending human validation and safety profiling.
Key Findings
- CSEO mitigated LPS-induced lung pathology, edema, inflammatory infiltration, and reduced MPO/NE activity and ROS, while inhibiting NF-κB activation.
- CSEO dose-dependently inhibited neutrophil adhesion to ICAM-1 and chemotaxis toward CXCL1 in vitro.
- Eucalyptol was identified as the active component: it bound β2 integrin (MST Kd ~19.5 μM), disrupted β2 integrin/ICAM-1 interaction, and suppressed neutrophil adhesion and chemotaxis.
- In vivo eucalyptol administration replicated CSEO’s protective effects, reducing ALI severity and neutrophil recruitment.
Methodological Strengths
- Multi-tier validation across in vivo mouse ALI model, in vitro functional assays, and biophysical binding (CETSA, DARTS, MST).
- Mechanistic specificity demonstrated by direct disruption of β2 integrin/ICAM-1 interaction and identification of an active constituent.
Limitations
- Preclinical animal model; human efficacy, pharmacokinetics, and safety are unknown.
- Potential off-target effects of eucalyptol and optimal dosing/regimen were not established.
Future Directions: Evaluate β2 integrin-targeting by eucalyptol and analogs in additional neutrophil-driven disease models (e.g., viral pneumonia, ARDS), define PK/PD and safety, and explore structure–activity relationships to improve potency and specificity.
ETHNOPHARMACOLOGICAL RELEVANCE: Chimonanthus salicifolius S. Y. Hu (Salicaceae), known as "Liu Ye La Mei," is traditionally used by the She ethnic minority in China to treat respiratory ailments including cough, asthma, and bronchitis. This ethnobotanical background provides a strong rationale for investigating its potential therapeutic value in acute lung injury (ALI). AIM OF THE STUDY: This study aimed to evaluate the protective effects of the essential oil from Chimonanthus salicifolius (CSEO) against lipopolysaccharide (LPS)-induced ALI in mice and to elucidate the underlying mechanisms. METHODS: ALI was induced in C57BL/6 mice by intratracheal LPS instillation, with separate cohorts pretreated intraperitoneally with CSEO or its component eucalyptol. In vivo therapeutic efficacy was evaluated by assessing lung histopathology, pulmonary edema, BALF inflammatory markers, and neutrophil activation status. In vitro, the effects of CSEO and eucalyptol on key neutrophil functions were assessed, including adhesion to ICAM-1 and chemotaxis (Transwell, Zigmond assays). The mechanism was investigated by evaluating interference with the β2 integrin/ICAM-1 interaction using competitive ELISA and co-immunoprecipitation. Following the identification of eucalyptol as a lead candidate via molecular docking, direct eucalyptol-β2 integrin binding was confirmed using multiple biophysical methods (CETSA, DARTS, MST). RESULTS: CSEO administration significantly ameliorated LPS-induced lung pathology, pulmonary edema, inflammatory cell infiltration, and suppressed MPO/NE activity and ROS levels in lung tissues. CSEO also reduced the production of pro-inflammatory cytokines and inhibited NF-κB pathway activation in the lungs. In vitro, CSEO dose-dependently inhibited neutrophil adhesion to ICAM-1 and chemotaxis towards CXCL1. Mechanistically, CSEO directly disrupted the binding between β2 integrin and ICAM-1 in both competitive ELISA and protein binding assays. Molecular docking identified eucalyptol as the CSEO constituent with the highest predicted binding affinity for β2 integrin. Subsequent experiments confirmed that eucalyptol significantly inhibited β2 integrin/ICAM-1 binding and suppressed neutrophil adhesion and chemotaxis in vitro. Biophysical assays provided strong evidence for a direct interaction between eucalyptol and β2 integrin, with MST determining a dissociation constant (Kd) of approximately 19.5 μM. Importantly, in vivo administration of eucalyptol replicated the protective effects of CSEO, significantly mitigating ALI severity, reducing inflammation, and inhibiting neutrophil recruitment and activation markers. CONCLUSIONS: CSEO demonstrates significant therapeutic potential against ALI by inhibiting neutrophil trafficking. Its key component, eucalyptol, directly antagonizes the β2 integrin/ICAM-1 interaction, leading to reduced neutrophil adhesion and chemotaxis. This work provides scientific evidence for the traditional use of C. salicifolius and identifies eucalyptol as a promising β2 integrin-targeting agent for treating ALI.
2. Single-Incision Laparoscopic Endorectal Pull-Through for Hirschsprung's Disease in Neonates: A Prospective Study on Medium-Term Outcomes.
In 23 neonates undergoing SILEP, there were no intraoperative complications or conversions, median stay was short, and medium-term bowel function was good-to-excellent in 84% with highly favorable scar cosmesis. These prospective findings support safety and feasibility, with complication rates acceptable for neonatal HD.
Impact: Provides prospective, medium-term outcomes for SILEP in neonates with standardized functional (BFS) and cosmetic (MSS) metrics, addressing a knowledge gap in pediatric minimally invasive surgery.
Clinical Implications: SILEP can be considered a safe, cosmetically favorable option for neonatal Hirschsprung’s disease in experienced centers, while comparative and long-term studies are still needed to define advantages versus conventional laparoscopy.
Key Findings
- No intraoperative complications or conversions in 23 neonates; mean operative time 53.8 ± 11.9 min; mean hospital stay 4.5 ± 1.1 days.
- Medium-term bowel function was good-to-excellent in 84% (mean BFS 17.5 ± 2.0) at ~45 months follow-up.
- Cosmetic outcomes were favorable with a mean MSS of 6.1 ± 1.4; reoperation 4.3% and enterocolitis 17.4%.
Methodological Strengths
- Prospective design with standardized outcome measures (BFS, MSS).
- Medium-term follow-up (~45 months) in a neonatal cohort.
Limitations
- Single-center, small sample size (n=23) without a control group.
- Level III evidence; generalizability and long-term outcomes beyond ~4 years remain uncertain.
Future Directions: Conduct multicenter comparative studies versus conventional laparoscopy with longer follow-up, including objective continence, quality-of-life, and blinded scar assessment.
BACKGROUND: Single-incision laparoscopic endorectal pull-through (SILEP) has gained attention as a minimally invasive alternative to conventional laparoscopic surgery (CLS) for Hirschsprung's disease (HD). While SILEP offers superior cosmetic outcomes and reduced postoperative morbidity, its feasibility, safety, and functional outcomes in neonates remain underexplored. This study aimed to prospectively evaluate the outcomes of SILEP in neonates with HD. PATIENTS AND METHODS: Between January 2020 and December 2021, 23 neonates (≤28 days of age) underwent SILEP at our institution. The procedure involved a 1.5 cm supra-umbilical incision with three fascial punctures for instrument placement, followed by laparoscopic mobilization and modified Soave endorectal pull-through. Perioperative outcomes, postoperative complications, bowel function (BFS), and scar cosmesis (MSS) were assessed. RESULTS: The mean age was 22.3 ± 3.2 days (range: 17-28 days). The mean operative time was 53.8 ± 11.9 min, and the mean hospital stay was 4.5 ± 1.1 days. No intraoperative complications or conversions were recorded. The reoperation rate was 4.3 %, and enterocolitis occurred in 17.4 % of patients. At a mean follow-up of 45.2 ± 3.9 months, 84 % of patients achieved good-to-excellent bowel function (mean BFS = 17.5 ± 2.0). Cosmetic outcomes were highly favorable (mean MSS = 6.1 ± 1.4). CONCLUSION: SILEP is a safe and feasible approach for managing HD in neonates, demonstrating favorable medium-term bowel function and excellent cosmetic outcomes. While the results are encouraging, further comparative and long-term studies are necessary to clarify its advantages over conventional approaches. LEVEL OF EVIDENCE RATING: Level III.
3. Comparative efficacy and safety of newest generation minimally invasive techniques in hysterectomy: A meta-analysis of miniature laparoscopy versus single-port laparoscopy.
Across comparative studies, MLS and LESS showed similar operative metrics and complication rates in hysterectomy, but MLS yielded lower early postoperative pain at 2 and 24 hours. Cosmetic outcomes were underreported, highlighting a gap for future trials.
Impact: Synthesizes current evidence to refine surgical choice between two advanced minimally invasive platforms, identifying a consistent early pain advantage with MLS.
Clinical Implications: When prioritizing early postoperative comfort without compromising safety, miniature laparoscopy may be favored over single-port laparoscopy for hysterectomy; comprehensive assessment should also incorporate cosmesis and longer-term recovery in future studies.
Key Findings
- No significant differences in operative time (MD 2.89, P=0.29), estimated blood loss (MD 0.79, P=0.80), or hospital stay (MD -0.11, P=0.18) between MLS and LESS.
- MLS had lower VAS pain at 2 h (MD -1.40, P=0.003) and 24 h (MD -0.67, P=0.001); pain at 8 h was similar (MD -0.33, P=0.07).
- Intraoperative (OR 0.703, P=0.634) and postoperative complications (OR 1.33, P=0.5) and conversion rates (OR 1.79, P=0.29) were comparable.
Methodological Strengths
- Meta-analytic synthesis using standardized effect measures (MD, OR) with 95% CIs.
- Direct head-to-head comparison of two contemporary minimally invasive platforms.
Limitations
- Heterogeneity, study designs, and risk of bias details were not specified; PRISMA compliance not stated.
- Cosmetic outcomes were underreported; total sample size and subgroup data were not provided in the abstract.
Future Directions: Prospective randomized comparisons with standardized reporting of cosmesis, pain trajectories, recovery metrics, and long-term outcomes are needed to define when MLS should be preferred over LESS.
BACKGROUND: Laparo-Endoscopic Single-Site Surgery (LESS) and MiniLaparoscopy are two new minimally invasive techniques that have gained popularity in the field of gynecologic surgery. This meta-analysis aims to compare the efficacy and safety outcomes of MLS and LESS in hysterectomy. METHODS: We performed a systematic review and meta-analysis of the MLS and LESS techniques for performing hysterectomy. Meta-analyses were performed using RevMan software we used mean differences and odds ratios (OR) with 95% confidence intervals. RESULTS: Our analysis found no significant differences in operative time (MD = 2.89, P = 0.29) or estimated blood loss (MD = 0.79, P = 0.80). The length of hospital stay was also similar (MD = -0.11, P = 0.18). In terms of postoperative pain, MLS had significantly lower VAS scores at 2 h (MD = -1.40, P = 0.003) and 24 h postop (MD = -0.67, P = 0.001), although pain scores were comparable at 8 h (MD = -0.33, P = 0.07). There was no difference in the duration of the time to first flatus between the techniques (MD = -0.63, P = 0.65). The incidence of intraoperative (OR = 0.703, P = 0.634) and postoperative (OR = 1.33, P = 0.5) complications was also similar for both techniques, as was the rate of conversion (OR = 1.79, P = 0.29). CONCLUSION: Results for both techniques were similar, but MLS may provide better postoperative pain relief at specific time intervals. Further studies with larger sample sizes and comprehensive data on cosmetic outcomes are necessary to confirm these results and identify any additional advantages.